• Net sales amounted to TSEK 2,800 (2,030).
• The loss after tax amounted to TSEK 10,207 (11,506).
• The loss per share amounted to SEK 0.61 (0.69).
• The cash flow from current operations was negative in the amount of TSEK 8,842 (9,990).
• The gross margin reached 58.0% (52.1%).
• Electrode sales volume increased by 85% and reached 7,180 (3,872) units. Repeat sales of electrodes to existing customers increased by 97%.

• Net sales amounted to TSEK 9,276 (6,899).
• The loss after tax amounted to TSEK 39,594 (44,215).
• The loss per share amounted to SEK 2,38 (2.66).
• The cash flow from current operations was negative in the amount of TSEK 37,956 (37,482).
• The gross margin increased to 54.5% (52.0%).
• Electrode sales volume increased by 53% and reached 23,724 (15,478) units. Repeat sales of electrodes to existing customers increased by 64%.

• Sales in the company's key market Germany continue to grow and increased by 24% in the quarter following a further improvement in electrode sales. Total sales increased by 38%
• SciBase received the first multi system (6) order from a large US dermatology practice group. Advanced Dermatology, P.C. is a group of over 40 dermatology practices in the New York tri-state area.
• SciBase received an order from the new dermatology clinic at the Mount Sinai hospital in New York, one of the most prestigious dermatology centers in the US.
• Thomas Eklund resigned from SciBase and other Board positions due to lack of time.

• No significant events have occurred since the end of the period.

  Oct 1 - Dec 31 Jan 1 - Dec 31
THE GROUP 2019 2018 2019 2018
Net sales, SEK ths 2 800 2 030 9 276 6 899
Gross margin, % 58,0% 52,1% 54,5% 52,0%
Equity/Asset ratio, % 69,4% 88,1% 69,4% 88,1%
Net indebtness, multiple 0,44 0,13 0,44 0,13
Cash equivalents, SEK ths 26 456 67 514 26 456 67 514
Cashflow from operating -8 842 -9 990 -37 956 -37 482
activities, SEK ths
Earnings per share -0,61 -0,69 -2,38 -2,66
(before and after
dilution), SEK
Shareholder's equity per 1,93 4,30 1,93 4,30
share, SEK
Average number of shares, 16 618 16 618 16 618 16 618
000'
Number of shares at 16 618 16 618 16 618 16 618
closing of period, 000'
Share price at end of 4,36 3,10 4,36 3,10
period, SEK
Number of sold 7 180 3 872 23 724 15 478
electrodes, pieces
Average number of 18 19 18 19
employees

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 21, 2020.

Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

Certified Advisor: 
Avanza AB 
Phone: +46 8 409 421 20 
Email: corp@avanza.se

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.